The VEGFR small-molecule inhibitors of angiogenesis show promise for oncology patients. These rationally designed inhibitors are being tailored for use in specific malignancies and will have a pivotal role in personalized medicine. The authors discuss the potential of these agents for treating tumors such as metastatic renal-cell carcinoma, GIST and hepatocellular carcinoma.
- S. Percy Ivy
- Jeannette Y. Wick
- Bennett M. Kaufman